Abstract 176P
Background
Neuroendocrine tumors are tumors that originate from endocrine cells in various organs, and show very heterogeneous characteristics, and their incidence is gradually increasing. Among them, neuroendocrine tumors originating from the pancreas are divided into functional tumors and non-functional tumors according to the secretion function of hormones. Therefore, we aimed to find protein biomarkers for diagnosis and differential diagnosis of pancreatic neuroendocrine tumor (PNET) through proteomic analysis of human blood.
Methods
A total of 60 human plasma samples were collected from 17 PNETs, 23 PDACs and 20 healthy donors, and liquid chromatography-mass spectrometry (LC-MS) proteomics analysis was performed on 60 human raw data. Identification and label-free quantification were performed through the swissprot protein sequence database. To investigate the function of CD163 among these three biomarker candidates, CD163-expressing cell lines were generated and 3 kinds of experiments were conducted. Additionally, to investigate the correlation between CD163 expression and cells, CBC analysis was performed by collecting blood and tumor tissues from mice transplanted with PNET and PDAC cell lines.
Results
An average of 549 protein lists were secured through LC-MS proteomics analysis using 60 samples, proteomes increased or decreased with disease were analyzed and classified through quantitative evaluation, and ACTR3, CD163, and LECT2 increased in PNET were selected as candidates for diagnostic biomarkers. The diagnostic AUC to differentiate PNET from HD was 0.971 for CD163 and the differential AUC to distinguish between PNET and PDAC was 0.870 for CD163. Additionally, CD163 was confirmed in the blood and tumor tissues of mice transplanted with PNET and PDAC cell lines, and significant results were obtained in PNET. Among the three biomarkers, CD163 was knocked-in to the PNET cell line to confirm the effect of CD163 on PNET.
Conclusions
These three markers will be used to identify molecular biological mechanisms for the generation and progression of PNET, and to study their function as markers that can simultaneously predict diagnosis and treatment response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
49P - Survival outcomes of HER2-positive breast cancer patients treated with neoadjuvant therapy at a single cancer centre in India
Presenter: Minit Shah
Session: Poster Display
Resources:
Abstract
50P - A nationwide retrospective cohort study of the response to neoadjuvant chemotherapy between HER-2 low and HER-2 negative non-metastatic breast cancer in Qatar: A real-world analysis
Presenter: Ahmed Kardousha
Session: Poster Display
Resources:
Abstract
51P - Four-year outcomes of hypofractionated postmastectomy radiation therapy of 39 Gy in 13 fractionations
Presenter: Sevinj Gahramanova
Session: Poster Display
Resources:
Abstract
52P - A comparative study to assess volumetric and dosimetric profile of heart and lung in patients undergoing left sided post mastectomy radiotherapy: Continuous positive airway pressure (CPAP) versus free breathing (FB) techniques
Presenter: Pritanjali Singh
Session: Poster Display
Resources:
Abstract
29P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: Shruti Kahol
Session: Poster Display
Resources:
Abstract
53P - Radiotherapy utilization rate for breast cancer in Indonesia: A call for empowering cancer care
Presenter: Donald Manuain
Session: Poster Display
Resources:
Abstract
58P - Safety and pharmacokinetics (PK) of vepdegestrant in Japanese patients with estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Results from a Japanese phase I study
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
59P - Comprehensive genomic profiling (CGP) unravels druggable targets in breast carcinoma (BC): A single institutional experience
Presenter: Gautam Balaram
Session: Poster Display
Resources:
Abstract
60P - A study of gene alterations in Asian patients with late stage and recurrent breast cancer
Presenter: Po-Sheng Yang
Session: Poster Display
Resources:
Abstract
61P - Tumor cell-released autophagosomes (TRAPs) remodel the breast tumor microenvironment by inducing the formation of inflammatory cancer-associated fibroblasts (CAFs)
Presenter: Chengdong Wu
Session: Poster Display
Resources:
Abstract